Pfizer Quality Improvement Request for Proposals: Improving the Quality and Standardization of Pneumococcal Diagnostic Pathways in Pediatric and Adult Populations
Supports quality improvement projects in Italy to standardize and optimize pneumococcal diagnostic pathways, improve surveillance data, and foster clinician-laboratory collaboration.
Funder: Pfizer Inc.
Due Dates: October 19, 2026 (Submission deadline, full application)
Funding Amounts: Up to EUR 50,000 per project (max 2 years); total program budget EUR 300,000
Summary: Supports quality improvement projects in Italy to standardize and optimize pneumococcal diagnostic pathways, enhancing data quality and collaboration.
Key Information: Projects must focus on quality improvement, not clinical research; only organizations (not individuals) are eligible.
Description
This grant opportunity from Pfizer Inc. is designed to support quality improvement initiatives that aim to optimize and standardize microbiological diagnostic pathways for Streptococcus pneumoniae in both pediatric and adult populations in Italy. The program seeks projects that implement evidence-based practices, enhance diagnostic processes, improve the completeness and reliability of serotype surveillance data, and foster collaboration between clinicians and laboratories. Eligible projects may focus on standardizing diagnostic bundles, optimizing sample management, integrating advanced diagnostics into routine clinical practice, and developing educational and training activities. The overall goal is to address gaps in diagnostic performance and improve public health reporting related to pneumococcal disease.
